<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00251238</url>
  </required_header>
  <id_info>
    <org_study_id>523052.01.002</org_study_id>
    <nct_id>NCT00251238</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon</brief_title>
  <official_title>Efficacy and Tolerability of Ginkgo Biloba Extract EGb 761® in Patients With Raynaud´s Phenomenon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VSM Geneesmiddelen b.v.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VSM Geneesmiddelen b.v.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the efficacy and safety of EGb 761® in patients with
      the primary Raynaud phenomenon, with regards to the frequency, duration and severity of
      vasospastic attacks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite more than 150 years of research into the pathophysiology of Raynaud´s phenomenon it
      is still not understood sufficiently. Three mean mechanisms responsible for Raynaud´s
      phenomenon are discussed and fall into the following three categories:

        -  neurological malfunction

        -  pathological blood vessel wall and blood cell interactions

        -  inflammatory and immunological responses Based on these concepts different classes of
           drugs have been tested. Although some therapies have shown effects, prolongation of the
           therapy is often difficult due to side-effects.

      Considering a prevalence of 5-10% in the general population, there is still a place and
      probably a need for the development of new treatment concepts. Ginkgo biloba has shown to
      have anti-oxidative and anti-platelet activities. In a small placebo controlled trial in
      patients with the Raynaud´s phenomenon promising results for the Ginkgo biloba extract were
      shown. EGb 761® is known to be safe and well tolerated. Based on the above considerations,
      EGb 761® may be an effective treatment for Raynaud´s phenomenon.

      Aim: To determine the efficacy and safety of EGb 761® in patients with Raynaud´s phenomenon
      on the frequency, duration, and severity of vasospastic attacks compared to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Vasospastic Attacks</measure>
    <time_frame>Number of Vasospastic Attacks per day, for up to 10 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Vasospastic Attacks</measure>
    <time_frame>minutes per day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Severity of Vasospastic Attacks</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>Severity of the complains due to Vasospastic Attacks was measured using a 10-steps likert scale.
The scale ranged between 0 and 10, with higher scores indicating more severe attacks.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Raynaud Disease</condition>
  <arm_group>
    <arm_group_label>Ginkgo biloba extract EGb 761</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving daily Ginkgo biloba extract EGb 761</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Receiving daily placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ginkgo biloba extract EGb 761</intervention_name>
    <description>daily Ginkgo biloba extract EGb 761</description>
    <arm_group_label>Ginkgo biloba extract EGb 761</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Ginkgo biloba</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary Raynaud´s phenomenon

          -  History of episodic digital or toe pallor

          -  Duration of Raynaud´s phenomenon at least 2 years

          -  Suffering form regular occuring attacks prior to enrolment

        Exclusion Criteria:

          -  Secondary Raynaud´s phenomenon

          -  Connective tissue disease

          -  Large vessel disease

          -  Cryoglobulinemia, cold agglutinins disease, thrombocytosis

          -  Concomitant pharmacological treatment with effects on the vasculature

          -  Pregnancy or lactation

          -  Severe internal or systemic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Department</last_name>
    <role>Study Director</role>
    <affiliation>VSM Geneesmiddelen b.v.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMC ST Radboud</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2005</study_first_submitted>
  <study_first_submitted_qc>November 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2005</study_first_posted>
  <results_first_submitted>January 12, 2015</results_first_submitted>
  <results_first_submitted_qc>May 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 22, 2017</results_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VSM Geneesmiddelen b.v.</investigator_affiliation>
    <investigator_full_name>Sebastian JH Bredie, MD, PhD</investigator_full_name>
    <investigator_title>SJH Bredie, internist, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Raynaud´s phenomenon</keyword>
  <keyword>Vasospastic attacks</keyword>
  <keyword>Ginkgo biloba</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raynaud Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention Group</title>
          <description>active treatment group, receiving oral film-coated tablet of 120-mg Ginkgo Biloba special extract (EGb 761) 2 times a day for 10 weeks, after an initial 2-week run-in phase</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>receiving matching placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention Group</title>
          <description>active treatment group, receiving film coated 120 mg Ginkgo Biloba special extract (EGb 761) two times a day for 10 weeks</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Receiving matching placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="13"/>
                    <measurement group_id="B2" value="49" spread="13"/>
                    <measurement group_id="B3" value="48" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Vasospastic Attacks</title>
        <time_frame>Number of Vasospastic Attacks per day, for up to 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>active treatment group (EGb 761)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>receiving placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Vasospastic Attacks</title>
          <units>attacks per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.6"/>
                    <measurement group_id="O2" value="2.0" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Vasospastic Attacks</title>
        <time_frame>minutes per day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>active treatment group (EGb 761)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>receiving placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Vasospastic Attacks</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" spread="63.0"/>
                    <measurement group_id="O2" value="50.9" spread="84.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Severity of Vasospastic Attacks</title>
        <description>Severity of the complains due to Vasospastic Attacks was measured using a 10-steps likert scale.
The scale ranged between 0 and 10, with higher scores indicating more severe attacks.</description>
        <time_frame>Baseline and 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>active treatment group (EGb 761)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>receiving placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Vasospastic Attacks</title>
          <description>Severity of the complains due to Vasospastic Attacks was measured using a 10-steps likert scale.
The scale ranged between 0 and 10, with higher scores indicating more severe attacks.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="2.3"/>
                    <measurement group_id="O2" value="-1.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention Group</title>
          <description>active treatment group (EGb 761)</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>receiving placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnoe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. SJH Bredie, MD, PhD</name_or_title>
      <organization>Radboud University Nijmegen, The Netherlands</organization>
      <phone>0031 24 3618819</phone>
      <email>bas.bredie@radboudumc.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

